AlphAIAlphAI — Financial news for AI agents
proactiveinvestors.com.auSEP 72 min read$AVR

Anteris Technologies appoints Brent Moen as chief financial officer

Anteris Technologies (ASX:AVR, NASDAQ:AVR) appointed Brent Moen as CFO, effective September 12, 2026. Moen has 25+ years of experience in finance, including roles at LifeLens, Tactile Systems, and Entellus Medical. Current CFO Matthew McDonnell will transition to head of Australia. Anteris develops medical devices for structural heart disease, including the DurAVR® Transcatheter Heart Valve.

Original reporting
proactiveinvestors.com.au
Published Sep 7, 2026, 12:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 7, 2026, 1:18 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Anteris Technologies appoints Brent Moen as chief financial officer — source image
Source · proactiveinvestors.com.au
Decision brief

The 30-second read

$AVRNeutralLow
01

Why it matters

The CFO appointment is a standard corporate action with modest informational value for traders.

02

Market read

Executive change provides a fresh data point for investors but is unlikely to drive significant price movement.

03

What to watch

Moen's prior experience in med‑tech M&A could hint at future acquisition activity.

Relevance 5/10Novelty 5/10Timing: effective Sep 12 2026

Background

Anteris Technologies (ASX:AVR, NASDAQ:AVR) develops transcatheter heart valve devices.

Company-level read

Ticker impact

$AVRNeutralMedium confidence
Context

Anteris Technologies announced the appointment of Brent Moen as chief financial officer, effective September 12, 2026.

Expected impact

Limited short‑term impact; potential modest upside if market views the hire positively.

Evidence & confidence

Executive changes are material but typically do not move the stock dramatically unless tied to a strategic shift.

Market effects

Sector

May signal continued focus on med‑tech financing within the sector.

Regional

Limited impact on Australian and US markets.

Global

Low global relevance beyond Anteris investors.

Counterpoint

What could challenge this read

The CFO change could be a distraction; investors may wait for operational results before reacting.

Key entities

  • person
    Brent Moen

    New chief financial officer of Anteris Technologies.

  • company
    Anteris Technologies

    Medical device company focused on heart valve technology.

Read at source← All news

Also covered by

1 outlet

Related articles

AUG 12
$AVRMed

Anteris Advances DurAVR Toward Commercialization; PARADIGM Trial Expands U.S. Recruitment

Anteris Technologies Global Corp. (AVR) reported Q2 2026 results and said it secured U.S. Medicare reimbursement eligibility for PARADIGM Trial procedures. The company began U.S. recruitment, with first patients treated in May 2026, and said the trial is recruiting in the U.S., Denmark and the Netherlands. Net operating cash outflow was $20.8M; R&D expense was $23.4M.

rttnews.com5 min
AUG 12
$AVRMed

Anteris Technologies advances PARADIGM Trial in June quarter as US patient recruitment gets underway

Anteris Technologies (ASX:AVR, NASDAQ:AVR) said it advanced its pivotal PARADIGM Trial in the June quarter, enrolling and treating its first US patients after CMS Medicare reimbursement eligibility for qualifying procedures. Recruitment expanded to the US, Denmark and the Netherlands, with Canada and France receiving regulatory clearance. The trial targets about 1,000 patients. Net operating cash outflows were US$20.8m.

proactiveinvestors.com.au4 min
AUG 11
$AVRMedAI 8/10

Anteris Technologies Announces Results for the Second Quarter of 2026

Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) reported Q2 2026 results for the quarter ended June 30, 2026. It said CMS granted Medicare reimbursement eligibility for the PARADIGM Trial, U.S. recruitment began with first patients treated in May 2026, and the trial expanded to multiple regions. Net operating cash outflows were $20.8M; R&D expenses were $23.4M.

leaderpost.com6 min
AUG 11
$AVRLow

Anteris Technologies Global Corp. (AVR): Results of Operations and Financial Condition

Anteris Technologies Global Corp. (AVR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Anteris Technologies Announces Results for the Second Quarter of 2026 MINNEAPOLIS, United States and BRISBANE, Australia August 12, 2026 (AEST) Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global healthcare company committe

SEC EDGAR 8-K4 min
JUN 4
$AVRMed

Anteris Technologies Global (NASDAQ:AVR) Shares Up 12.6% – Should You Buy?

Anteris Technologies Global (NASDAQ:AVR) shares rose 12.6% to $10.0750 on Thursday, after closing at $8.95; the stock traded between $9.71 and $10.0750. Volume was 176,960 shares, down 84% vs. average. Analysts cited mixed views: Barclays raised its target to $18 (overweight), while Wall Street Zen moved to hold; consensus target is $16. In its May 12 earnings, the company reported -$0.28 EPS vs -$0.27 expected on $0.49M revenue vs $0.77M.

tickerreport.com5 min